Sinopharm Group Co (DE:X2S1)
FRANKFURT:X2S1
X2S1 Stock Chart & Stats
€11.10
€0.00(0.00%)
At close: 4:00 PM EST
€11.10
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€9.10 - €11.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.69B
Enterprise Value€92.34B
Total Cash (Recent Filing)€61.60B
Total Debt (Recent Filing)€108.65B
Price to Earnings (P/E)6.2
Beta0.38
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.35
Shares Outstanding268,362,150
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-4.39
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Nationwide Logistics NetworkSinopharm's nationwide logistics and sales network creates a durable distribution advantage across China. Scale and coverage reduce fulfillment risk, support strong supplier relationships, and provide a structural moat that sustains revenue reach and resilience versus smaller regional competitors.
Consistent Cash GenerationHistorical free cash flow covering most net income indicates strong cash conversion for a distribution business. Reliable cash generation supports dividends, working capital needs and potential deleveraging or reinvestment, enhancing long-term financial flexibility despite revenue cyclicality.
Diversified Healthcare ChannelsMultiple revenue streams—wholesale pharmaceuticals, medical devices/consumables and retail pharmacies—reduce dependency on any single channel or product. This structural diversification smooths volatility, allows margin mix optimization, and supports cross-selling and service expansion over time.
Bears Say
Top-line WeaknessSustained revenue decline erodes scale in a business with low per-unit margins and high fixed logistics costs. Continued top-line weakness reduces operating leverage, limits funding for network upgrades or growth initiatives, and increases reliance on margin or cost fixes to sustain profits.
Margin CompressionMaterial decline in gross and EBITDA margins leaves little buffer against cost inflation, policy-driven price pressure, or procurement changes. Narrow profitability constrains reinvestment and strategic flexibility, making earnings more sensitive to structural shifts in pricing or reimbursement.
Rising Leverage And Lower ReturnsA notable increase in leverage combined with declining ROE raises financial risk for a low-margin distributor. Higher debt amplifies interest and refinancing exposure, limits ability to pursue strategic investments, and reduces resilience to demand shocks or margin compression over the medium term.
Sinopharm Group Co News
X2S1 FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
Sinopharm Group Co lowest stock price was €9.10 and its highest was €11.80 in the past 12 months.
What is Sinopharm Group Co’s market cap?
Sinopharm Group Co’s market cap is €5.69B.
When is Sinopharm Group Co’s upcoming earnings report date?
Sinopharm Group Co’s upcoming earnings report date is Aug 31, 2026 which is in 72 days.
How were Sinopharm Group Co’s earnings last quarter?
Currently, no data Available
Is Sinopharm Group Co overvalued?
According to Wall Street analysts Sinopharm Group Co’s price is currently Overvalued.
Does Sinopharm Group Co pay dividends?
Sinopharm Group Co does not currently pay dividends.
What is Sinopharm Group Co’s EPS estimate?
Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Group Co have?
Sinopharm Group Co has 268,362,150 shares outstanding.
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sinopharm Group Co?
Currently, no hedge funds are holding shares in DE:X2S1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinopharm Group Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.83%
12-Months-Change
Fundamentals
Return on Equity
8.62%
Trailing 12-Months
Asset Growth
3.79%
Trailing 12-Months
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharmaceutical Distribution segment is responsible for supplying a wide array of pharmaceutical products to various healthcare entities, including hospitals, clinics, and retail pharmacies. This segment also provides comprehensive logistics and value-added services to both domestic and international manufacturers and suppliers of pharmaceutical and healthcare items. The Medical Devices segment focuses specifically on the distribution of medical equipment. Through its Retail Pharmacy segment, the company operates and franchises an extensive chain of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment encompasses the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core activities, Sinopharm Group also engages in property rental and management, distributes specialized products such as Chinese herbal medicines, antibiotics, and biological products, and offers a suite of services. These include IT development, medicine, business, health, and market information consulting, international trade (import/export of goods and technology), market investigation, and convention and exhibition services. Furthermore, the company is involved in medical project investment, consulting, and technology training. To enhance its commercial capabilities and transformation, Sinopharm Group Co. Ltd. maintains a strategic partnership with I-Mab. Founded in 2003, the company is headquartered in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Technical Analysis
Options Prices
Currently, No data available
---